KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
Determination of the mutations' status in the KRAS and NRAS genes is a necessary requirement in the treatment of patients with colorectal cancer (CRC). Patients with certain mutations in the KRAS and NRAS genes are resistant to anti-EGFR drug therapy and have a lower median survival rate than t...
Guardado en:
Autores principales: | Olga I. Brovkina, Alexey G. Nikitin |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
Eco-vector
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f188be48a67348c79d1798ffd8d2b72d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Associations of Polymorphisms Localized in the 3′UTR Regions of the <i>KRAS</i>, <i>NRAS</i>, <i>MAPK1</i> Genes with Laryngeal Squamous Cell Carcinoma
por: Ruta Insodaite, et al.
Publicado: (2021) -
CRISPR and KRAS: a match yet to be made
por: Guzide Bender, et al.
Publicado: (2021) -
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu X, et al.
Publicado: (2019) -
Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer
por: Eunsung Jun, et al.
Publicado: (2021) -
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
por: Gongmin Zhu, et al.
Publicado: (2021)